Apple's Secret Weapon Isn’t an iPhone Feature This Year
(Bloomberg) -- In past years, when Apple Inc. didn't have a new iPhone design, it still had a breakthrough new feature: video recording in 2009, the Siri digital assistant in 2011, a fingerprint scanner in 2013, and 3D Touch in 2015.
This year, Apple's secret weapon isn't a particular feature, but a clever pricing strategy and myriad options for storage, colors, and screen sizes. While no one swooned over product advancements, the moves unveiled on Wednesday will likely pay off financially, highlighting the company's entrenched status as the top provider of consumer technology in the western world.
"While the Apple event went largely as expected, the new iPhone lineup should provide upside" for unit sales and average selling prices, Gene Munster, a longtime Apple analyst, said. The company showed "mastery of pricing tiers, which will extract more revenue per customer," he added.
The Cupertino, California-based technology giant took the wraps off the iPhone Xs, iPhone Xs Max, and iPhone Xr, three new models based on the iPhone X design and feature set from last year.
The iPhone Xs adds a faster processor and improved camera functionality, while the iPhone Xs Max has a much bigger screen. The Xr version brings iPhone X features like the edge-to-edge screen and Face ID to more people with its $750 price, $250 less than last year's flagship.
Apple is adjusting to a smartphone industry that has stalled at about 1.5 billion devices sold each year. Rather than persuading users to upgrade to the most-advanced, expensive phone each year, Apple's goal these days is to steadily raise average prices, while expanding the total number of active devices to support sales of accessories and digital services like streaming music and video.
"Apple's focus appears to be shifting away from product replacement cycles and more towards profitability and Services narrative, which is a positive in a mature smartphone market," Amit Daryanani, an analyst at RBC Capital Markets, wrote in a note to investors.
Apple shares slipped 1.2 percent to close at $221.07 on Wednesday. The stock has jumped more than 30 percent this year, making Apple the first public company worth $1 trillion.
Read more: Shiny New IPhones Underscore Apple's Growth Problem
The lower price of the Xr may increase Apple's installed base of devices, spurring sales of accessories like the Apple Watch and digital services. The cheaper and larger-screen models are expected to entice customers with older iPhones to upgrade, helping Apple distribute its latest software features to more users.
Read about FDA approval of the Apple Watch's new ECG feature.
Piper Jaffray analyst Mike Olson surveyed iPhone owners who didn't upgrade to last year's X model, and about 40 percent of these people said they stuck with existing devices because the iPhone X was too expensive or too small. Now these users have options, Olson wrote Wednesday in a note.
Another way to tackle a slow-growing smartphone market is to raise prices. Apple's latest iPhone line-up may well pull this off, too. Apple lowered the price of the iPhone 7 to $449, but discontinued the cheapest iPhone SE. And the new iPhone Xs Max costs as much as $1,449. So the overall price range is $449 to $1,449 now, up from $349 to $1,149 previously.
Munster expects average iPhone selling prices to reach $791 in Apple's 2019 fiscal year. That's up from $652 in the 2017 fiscal year, according to data compiled by Bloomberg.
To contact the reporter on this story: Mark Gurman in San Francisco at mgurman1@bloomberg.net
To contact the editors responsible for this story: Tom Giles at tgiles5@bloomberg.net, Alistair Barr, Andrew Pollack
©2018 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.